Retinoic acid syndrome

Retinoic acid syndrome is a potentially life-threatening medical condition that primarily occurs in patients with acute promyelocytic leukemia (APL) who are treated with all-trans retinoic acid (ATRA). The syndrome is characterized by fever, respiratory distress, weight gain, and other symptoms.

Etiology[edit | edit source]

Retinoic acid syndrome is most commonly associated with the use of ATRA in the treatment of APL. ATRA is a derivative of Vitamin A and is used to induce differentiation of the immature leukemic cells. However, in some patients, this can lead to a severe inflammatory response known as retinoic acid syndrome.

Symptoms[edit | edit source]

The symptoms of retinoic acid syndrome can vary, but often include fever, difficulty breathing, weight gain, and edema. Other symptoms can include chest pain, hypotension, and thrombosis. In severe cases, the syndrome can lead to respiratory failure and death.

Diagnosis[edit | edit source]

Diagnosis of retinoic acid syndrome is primarily based on clinical symptoms. However, laboratory tests such as complete blood count (CBC), blood chemistry, and coagulation tests may be used to support the diagnosis.

Treatment[edit | edit source]

Treatment of retinoic acid syndrome involves discontinuation of ATRA and administration of dexamethasone. In severe cases, hospitalization may be required.

Prognosis[edit | edit source]

With prompt recognition and treatment, the prognosis for retinoic acid syndrome is generally good. However, if left untreated, the syndrome can be fatal.